Size | Price | Stock | Qty |
---|---|---|---|
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
Other Sizes |
|
Targets |
5-HT3 receptor ( Ki = 0.091 nM )
|
---|---|
ln Vitro |
Ramosetron Hydrochloride (YM-060) has very low afinity for nicotinic and GABA receptors. YM060 also exhibits low affinity for histamine H1 and H2 receptors, alpha-1, atpha-2, beta-1, beta-2, and 5-HT1-like and 5-HT2 receptors, according to in vitro research. Anticipated 5-HT4 receptor blocking activity of YM-060 is negative[2].
|
ln Vivo |
Ramosetron has been shown to potently inhibit abnormal defecation in animals that is caused by stress. Ramosetron has potent, rapid-onset, and long-lasting inhibitory effects on rats' CFS-induced defecation, but has no effect on regular defecation. Ramosetron's inhibitory effect started to take effect right away after dosage and persisted for several hours[1].
|
Animal Protocol |
Sprague-Dawley rats
0.01, 0.03, 0.1 mg/kg oral |
References |
Molecular Formula |
C17H18CLN3O
|
---|---|
Molecular Weight |
315.801
|
Exact Mass |
315.11
|
Elemental Analysis |
C, 64.66; H, 5.75; Cl, 11.23; N, 13.31; O, 5.07
|
CAS # |
132907-72-3
|
Related CAS # |
132907-72-3 (HCl); 132036-88-5
|
Appearance |
Solid powder
|
SMILES |
CN1C=C(C2=CC=CC=C21)C(=O)[C@@H]3CCC4=C(C3)NC=N4.Cl
|
InChi Key |
XIXYTCLDXQRHJO-RFVHGSKJSA-N
|
InChi Code |
InChI=1S/C17H17N3O.ClH/c1-20-9-13(12-4-2-3-5-16(12)20)17(21)11-6-7-14-15(8-11)19-10-18-14;/h2-5,9-11H,6-8H2,1H3,(H,18,19);1H/t11-;/m1./s1
|
Chemical Name |
(1-methylindol-3-yl)-[(5R)-4,5,6,7-tetrahydro-3H-benzimidazol-5-yl]methanone;hydrochloride
|
Synonyms |
YM-060; YM 060; YM060; Ramosetron hydrochloride; Ramosetron HCl
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: 32~63 mg/mL (101.3~199.5 mM)
Water: ~63 mg/mL Ethanol: ~1 mg/mL |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 25 mg/mL (79.16 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication (<60°C).
 (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.1666 mL | 15.8328 mL | 31.6656 mL | |
5 mM | 0.6333 mL | 3.1666 mL | 6.3331 mL | |
10 mM | 0.3167 mL | 1.5833 mL | 3.1666 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT06166615 | Not yet recruiting | Drug: Ramosetron Drug: Psyllium |
Fecal Incontinence | Seoul National University Hospital | December 15, 2023 | Phase 2 Phase 3 |
NCT05577845 | Recruiting | Drug: Ramosetron | LARS - Low Anterior Resection Syndrome |
Seoul National University Hospital |
March 27, 2023 | Not Applicable |
NCT03278522 | Completed | Drug: Ramosetron | PONV Prolonged QTc Interval |
Konkuk University Medical Center | July 1, 2017 | Phase 4 |
NCT02076529 | Completed | Drug: Ramosetron 0.3mg Drug: Ramosetron 0.45mg Drug: Ramosetron 0.6mg |
Colon Cancer | Chonnam National University Hospital |
October 2012 | Not Applicable |
NCT01392794 | Completed | Drug: YM060 | Healthy Plasma Concentration of YM060 |
Astellas Pharma Inc | April 2011 | Phase 1 |